

Leber Congenital Amaurosis R&D Pipeline Analysis Report, H2-2018

https://marketpublishers.com/r/L5A19460460EN.html

Date: August 2018

Pages: 50

Price: US\$ 2,200.00 (Single User License)

ID: L5A19460460EN

Abstracts

Leber Congenital Amaurosis Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Leber Congenital Amaurosis pipeline products.

The Leber Congenital Amaurosis pipeline guide presents complete overview of drugs currently being developed for Leber Congenital Amaurosis. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Leber Congenital Amaurosis pipeline candidate.

Research and Development progress along with latest news related to each of the Leber Congenital Amaurosis pipeline candidates is included.

Major companies participating in therapeutic development of Leber Congenital Amaurosis are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.

Amid strong interest for cure of Leber Congenital Amaurosis from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Leber Congenital Amaurosis clinical and pre clinical products.



The report assists in identifying potential upcoming companies and drugs in Leber Congenital Amaurosis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

SCOPE OF LEBER CONGENITAL AMAUROSIS PIPELINE REPORT INCLUDES

Panorama of Leber Congenital Amaurosis pipeline markets including statistics on therapeutic drugs and companies involved

Leber Congenital Amaurosis Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered

Leber Congenital Amaurosis pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Leber Congenital Amaurosis pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Leber Congenital Amaurosis pipeline therapeutics

REASONS TO BUY

Get clear understanding of the entire Leber Congenital Amaurosis pipeline, with details on active projects



Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Leber Congenital Amaurosis pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

Please Note: The report will be delivered in 2 working days after purchase



Contents

I. KEY FINDINGS

 Companies Investing in Leber Congenital Amaurosis Pipeline include Number of Companies with Leber Congenital Amaurosis projects in pre clinical Development

Number of Companies with Leber Congenital Amaurosis projects in Clinical Development

Leber Congenital Amaurosis Pipeline Companies based in Americas

Leber Congenital Amaurosis Pipeline Companies based in Europe

Leber Congenital Amaurosis Pipeline Companies based in Asia Pacific

Leber Congenital Amaurosis Pipeline Companies based in Rest of the World

2. Pipeline Candidates include

Leber Congenital Amaurosis Pipeline Agents in pre clinical/Discovery stage of Development

Leber Congenital Amaurosis Pipeline Agents in Clinical Development stage Leber Congenital Amaurosis Pipeline Therapeutic Compounds received special status Mechanism of Action of most pipeline Drugs

Small molecules among the Leber Congenital Amaurosis Pipeline agents

II. INSIGHTS INTO LEBER CONGENITAL AMAUROSIS PIPELINE

1. Disease Overview

Introduction to Leber Congenital Amaurosis

Symptoms and Causes of Leber Congenital Amaurosis

Treatment or Prevention Options for Leber Congenital Amaurosis

Other Details

2. Phase wise Pipeline Compounds

Leber Congenital Amaurosis Pipeline Pre Clinical/Discovery stage Drugs

Leber Congenital Amaurosis Pipeline Phase 1 stage Drugs

Leber Congenital Amaurosis Pipeline Phase 2 stage Drugs

Leber Congenital Amaurosis Pipeline Phase 3 stage Drugs

Leber Congenital Amaurosis Pipeline Pre Registration stage Drugs

- 3. Company wise Leber Congenital Amaurosis Pipeline Compounds
- 4. Leber Congenital Amaurosis Pipeline by Mechanism of Action

III. LEBER CONGENITAL AMAUROSIS PIPELINE COMPOUND DETAILS



Drug Details

1. Snapshot

Name of the Therapeutic Agent

Originator

Developing Company

Co Developer/License Partner

Orphan Drug/Fast Track/Designation

Development Phase

- 2. Drug Overview
- 3. Mechanism of Action
- 4. Current Status
- 5. Clinical Trial Details

IV. LEBER CONGENITAL AMAUROSIS PIPELINE COMPANY BRIEFS

V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL LEBER CONGENITAL AMAUROSIS PIPELINE MARKET

VI. APPENDIX

- 1. About Us
- 2. Research Methodology
- 3. Contact Information

The report will be delivered within 2 working days after procurement. Some of the sections depicted above may be modified in accordance with relevancy and availability



I would like to order

Product name: Leber Congenital Amaurosis R&D Pipeline Analysis Report, H2-2018

Product link: https://marketpublishers.com/r/L5A19460460EN.html

Price: US\$ 2,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/L5A19460460EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970